ChiCTR2500096893 版本V1.0 版本创建时间2025/02/08 14:23:04 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2500096893 

最近更新日期:

Date of Last Refreshed on:

2025-02-08 14:22:57 

注册时间:

Date of Registration:

2025-02-08 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

布比卡因脂质体腰方肌阻滞对腹腔镜妇科手术后的疼痛的影响:一项随机对照试验

Public title:

Effect of quadratus lumborum block using bupivacaine liposome on pain control for patients undergoing laparoscopic gynecological surgery: a randomized controlled trial

注册题目简写:

English Acronym:

研究课题的正式科学名称:

布比卡因脂质体腰方肌阻滞对腹腔镜妇科手术后的疼痛的影响:一项随机对照试验

Scientific title:

Effect of quadratus lumborum block using bupivacaine liposome on pain control for patients undergoing laparoscopic gynecological surgery: a randomized controlled trial

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

张云慧 

研究负责人:

张云慧 

Applicant:

Yunhui Zhang 

Study leader:

Yunhui Zhang 

申请注册联系人电话:

Applicant telephone:

+86 138 1252 9034

研究负责人电话:

Study leader's
telephone:

+86 138 1252 9034

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

1204153892@qq.com

研究负责人电子邮件:

Study leader's E-mail:

1204153892@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

无锡市锡山区安镇街道大成路1128号

研究负责人通讯地址:

无锡市锡山区安镇街道大成路1128号

Applicant address:

1128 Dacheng Road, Xishan District, Wuxi, Jiangsu, China

Study leader's address:

1128 Dacheng Road, Xishan District, Wuxi, Jiangsu, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

无锡市锡山人民医院

Applicant's institution:

Xishan People’s Hospital of Wuxi City

研究负责人所在单位:

无锡市锡山人民医院

Affiliation of the Leader:

Xishan People’s Hospital of Wuxi City

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

xs2024ky065

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

无锡市锡山人民医院伦理委员会

Name of the ethic committee:

Ethics Committee of Xishan people’s Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2024-09-25 00:00:00

伦理委员会联系人:

吴丽君

Contact Name of the ethic committee:

Lijun Wu

伦理委员会联系地址:

无锡市锡山区安镇街道大成路1128号

Contact Address of the ethic committee:

1128 Dacheng Road, Xishan District, Wuxi, Jiangsu, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 510 8286 7901

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

无锡市锡山人民医院

Primary sponsor:

Xishan People’s Hospital of Wuxi City

研究实施负责(组长)单位地址:

无锡市锡山区安镇街道大成路1128号

Primary sponsor's address:

1128 Dacheng Road, Xishan District, Wuxi, Jiangsu, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

江苏

市(区县):

无锡

Country:

China

Province:

Jiangsu

City:

Wuxi

单位(医院):

无锡市锡山人民医院

具体地址:

无锡市锡山区安镇街道大成路1128号

Institution
hospital:

Xishan People’s Hospital of Wuxi City

Address:

1128 Dacheng Road, Xishan District, Wuxi, Jiangsu, China

经费或物资来源:

自筹

Source(s) of funding:

self-finance

研究疾病:

腹腔镜妇科手术  

Target disease:

laparoscopic gynecologic surgery

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

上市后药物 

Study phase:

4

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

观察布比卡因脂质体用于前路腰方肌阻滞对腹腔镜妇科手术后的镇痛效果。  

Objectives of Study:

To evaluate the efficacy of anterior quadratus lumborum block using bupivacaine liposome on pain control for patients undergoing laparoscopic gynecological surgery.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1)美国麻醉医师协会(ASA)分级为 I ~ III 级的受试者; 2)年龄≥ 18岁; 3)体重指数(BMI)在 18.5 ~ 30 kg/m^2之间; 4)择期行腹腔镜妇科手术患者。

Inclusion criteria

1) ASA class I-III; 2) Aged >=18 years; 3) BMI 18.5~30 kg/m^2; 4) Patients undergoing laparoscopic gynecological surgery.

排除标准:

1)对局麻药物或任何一种研究方案用药有过敏史; 2)存在认知功能障碍; 3)严重的心、肺、肝、肾等功能不全; 4)凝血功能异常; 5)慢性疼痛史或术前使用镇静剂或镇痛药。

Exclusion criteria:

1) History of allergy to local anesthetic drugs or any of the experimental medications; 2) Cognitive dysfunction; 3) Severe cardiac , pulmonary ,liver or kidney dysfunction; 4) Abnormal coagulation function ; 5) History of chronic pain or preoperative use of sedatives or analgesics.

研究实施时间:

Study execute time:

From 2025-02-10 00:00:00 To 2025-06-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2025-02-10 00:00:00 To 2025-06-30 00:00:00

干预措施:

Interventions:

组别:

LB组(布比卡因脂质体复合布比卡因组)

样本量:

68

Group:

LB group (liposomal bupivacaine plus bupivacaine group)

Sample size:

干预措施:

术前行前路腰方肌阻滞。双侧各注入布比卡因脂质体133mg+布比卡因37.5mg稀释至20ml。

干预措施代码:

Intervention:

Preoperative anterior quadratus lumborum block with 133mg liposomal bupivacaine (Jiangsu Hengrui, China) plus 37.5 mg bupivacaine diluted to 20ml on each side.

Intervention code:

组别:

BD组(布比卡因复合地塞米松组)

样本量:

68

Group:

BD group (bupivacaine plus dexamethasone group)

Sample size:

干预措施:

术前行前路腰方肌阻滞。双侧各注入布比卡因75mg+地塞米松4mg稀释至20ml。

干预措施代码:

Intervention:

Preoperative anterior quadratus lumborum block with 37.5 mg bupivacaine plus 4 mg dexamethasone diluted to 20ml on each side.

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

江苏 

市(区县):

无锡 

Country:

China

Province:

Jiangsu

City:

Wuxi

单位(医院):

无锡市锡山人民医院  

单位级别:

三乙 

Institution
hospital:

Xishan People’s Hospital of Wuxi City

Level of the institution:

Tertiary B

测量指标:

Outcomes:

指标中文名:

术后48 小时内的累积羟考酮消耗量

指标类型:

主要指标

Outcome:

Oxycodone consumption during first 48 h postoperatively

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后各时间点NRS疼痛评分

指标类型:

次要指标

Outcome:

NRS scores at different time after surgery

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后首次使用镇痛泵时间

指标类型:

次要指标

Outcome:

The duration of analgesia

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后各时间段羟考酮消耗量;

指标类型:

次要指标

Outcome:

Oxycodone consumption at various postoperative periods

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后不良反应

指标类型:

次要指标

Outcome:

Postoperative adverse effects

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后72小时疼痛评分的曲线下面积

指标类型:

次要指标

Outcome:

Area under the curve of pain scores during 0-72 hours postoperatively(AUC NRS 0-72)

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后72小时无阿片类药物状态

指标类型:

次要指标

Outcome:

Opioid-free state during 0-72 hours postoperatively

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

患者满意度

指标类型:

次要指标

Outcome:

Patient satisfaction

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age years

性别:

女性

Gender:

Female

随机方法(请说明由何人用什么方法产生随机序列):

使用SPSS统计软件26.0进行简单随机分组

Randomization Procedure (please state who generates the random number sequence and by what method):

Simple randomized allocation was performed using SPSS statistics 26.0

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

双盲。该实验采取盲法,患者及其家属以及术后随访统计分析的麻醉医师不知道分组情况,由实施操作的麻醉医师外的第三方负责配置试验药品。实施操作的麻醉医师不知道分组情况,且不参与术后随访。

Blinding:

Double blinded. The experiment was conducted in a blind way. Patients, their families and the anesthesiologist who followed up the statistical analysis after the operation did not know the group status, and a third party other than the anesthesiologist who performed the operation was responsible for the allocation of the experimental drug. The anesthesiologist performing the procedure was not aware of the grouping and did not participate in postoperative follow-up.

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

论文发表

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Research articles

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2025-02-08 14:22:57